Monday May 29th 2017

Laquinimod study published

Results of the phase III Bravo trial (comparing Laquinimod with beta interferon and placebo) show that, whilst it didn’t show a greater reduction in relapse rate, it does seem to reduce the rate of brain atrophy (loss of brain tissue). MS Research Australia Laquinimod – drugs in development (Source: Multiple Sclerosis Trust)

Link: 

Laquinimod study published

Leave a Comment

More from category

New sleep system helps profoundly disabled 5-year-old boy with complex care needs to get full night’s sleep
New sleep system helps profoundly disabled 5-year-old boy with complex care needs to get full night’s sleep

A 5-year-old boy, who is profoundly disabled and has complex needs, has been given his first full night’s sleep [Read More]

Revisions Underway to McDonald Criteria on MS Diagnosis Revisions Underway to McDonald Criteria on MS Diagnosis
Revisions Underway to McDonald Criteria on MS Diagnosis Revisions Underway to McDonald Criteria on MS Diagnosis

An expert panel is tackling the first revision to the multiple sclerosis diagnostic criteria in 7 years. Among proposed [Read More]

Connecticut State Budget Call to Action
Connecticut State Budget Call to Action

/About-the-Society/News/Connecticut-State-Budget-Call-to-Action [Read More]

A Surge of New Drug Data in Multiple Sclerosis A Surge of New Drug Data in Multiple Sclerosis
A Surge of New Drug Data in Multiple Sclerosis A Surge of New Drug Data in Multiple Sclerosis

Medscape sits down with two neurologists to discuss advances in multiple sclerosis as presented at this year's American [Read More]

Progress on Bills to Address Step Therapy
Progress on Bills to Address Step Therapy

/About-the-Society/News/Progress-on-Bills-to-Address-Step-Therapy [Read More]